A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Jeffrey Alan Sosman
Research Funding - Novartis
Muaiad Kittaneh
Research Funding - Novartis
Martijn P. J. K. Lolkema
Honoraria - Novartis
Michael Andrew Postow
No relevant relationships to disclose
Gary Schwartz
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Catherine Franklin
Employment or Leadership Position - Novartis
Alessandro Matano
Employment or Leadership Position - Novartis
Suraj Bhansali
Employment or Leadership Position - Novartis
Sudha Parasuraman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kevin Kim
Research Funding - Novartis